Please check your internet connection and try again.
# Potassium chloride
## Overview
Potassium chloride (KCL) is an essential electrolyte used to prevent or treat hypokalemia. It is available in oral and intravenous formulations.
## Primary Indications
* Treatment and prevention of hypokalemia.
## Adult Dosing
* **Oral:** Dosing varies based on the degree of hypokalemia and maintenance needs.
* Typical maintenance: 20-40 mEq (1.5-3 g) per day in divided doses.
* Treatment of hypokalemia: 40-100 mEq (3-7.5 g) per day in divided doses.
* Maximum oral dose: Typically not to exceed 100 mEq (7.5 g) per 24 hours, but may be guided by electrolyte levels and clinical response.
* **Intravenous (IV):** Dosing is highly individualized and depends on serum potassium levels and the urgency of correction.
* **Mild to moderate hypokalemia (serum K 2.5-3.5 mEq/L):** 20-40 mEq (1.5-3 g) added to a large volume IV fluid (e.g., 1000 mL NS or LR) infused over 4-10 hours.
* **Severe hypokalemia (serum K < 2.5 mEq/L) or symptomatic hypokalemia:** 40 mEq (3 g) may be administered rapidly via a central line, diluted in 500 mL of IV fluid, infused no faster than 20 mEq/hour (unless life-threatening and under cardiac monitoring).
* **Maximum IV infusion rate:** Generally not to exceed 20 mEq/hour. In life-threatening situations, rates up to 40 mEq/hour may be used with continuous cardiac monitoring and central access, but this carries significant risk of hyperkalemia and cardiac arrest.
* **Maximum single IV dose:** Generally limited to 40 mEq (3 g) per infusion bag and 100 mEq (7.5 g) per 24 hours, unless specific protocols for emergent situations are followed.
## Pediatric Dosing
* Dosing is based on ideal body weight and serum potassium levels. Local pediatric protocols should be consulted.
* **Oral:** Typical maintenance: 1-2 mEq/kg/day, not to exceed 3 g/day. Treatment of hypokalemia: up to 4 mEq/kg/day in divided doses.
* **Intravenous (IV):**
* **Maintenance:** 20-30 mEq/m²/day or 2-5 mEq/kg/day, as part of total parenteral nutrition or other IV fluids.
* **Correction:** 0.3-0.5 mEq/kg/dose infused over 1-3 hours, not to exceed 10-20 mEq/hour. Doses up to 1 mEq/kg/dose may be given in emergencies with cardiac monitoring. Maximum dose per 24 hours is typically 100 mEq/m²/day.
## Dose Adjustments
* **Renal Impairment:** Use with extreme caution. Potassium excretion is reduced in renal impairment, increasing the risk of hyperkalemia. Lower doses and frequent monitoring are essential. Avoid if possible in severe renal insufficiency.
## Contraindications
* Severe renal impairment.
* Conditions causing increased potassium levels (e.g., Addison's disease, untreated Addison's disease, acute dehydration, extensive tissue breakdown).
* Hyperkalemia.
* Certain cardiac conditions (e.g., heart block without a pacemaker).
* Known hypersensitivity to potassium chloride.
## Adverse Effects
* **Most Common:** Gastrointestinal upset (nausea, vomiting, diarrhea, abdominal pain), especially with oral administration.
* **Serious:** Hyperkalemia (potentially life-threatening) with symptoms including muscle weakness, fatigue, paresthesias, cardiac arrhythmias, and cardiac arrest. Esophageal or gastric ulceration and perforation with oral administration, particularly if taken with insufficient fluid or in patients with motility disorders.
* **Other:** Injection site reactions (pain, phlebitis) with IV administration.
## Key Drug Interactions
* **Potassium-sparing diuretics (e.g., spironolactone, amiloride, triamterene):** Additive effect, increasing the risk of hyperkalemia.
* **ACE inhibitors (e.g., lisinopril, enalapril) and Angiotensin II Receptor Blockers (ARBs) (e.g., losartan, valsartan):** Can increase serum potassium by reducing aldosterone production, increasing the risk of hyperkalemia.
* **NSAIDs (e.g., ibuprofen, naproxen):** May reduce the antihypertensive effect of potassium supplements and increase serum potassium.
* **Heparin:** May cause hyperkalemia by inhibiting aldosterone secretion.
* **Digoxin:** Hyperkalemia can increase the risk of digoxin toxicity; hypokalemia can increase the risk of digoxin toxicity.
## Monitoring
* **Essential:** Frequent serum potassium levels, especially during IV administration, with dose adjustments, or in patients with renal impairment or those taking interacting medications.
* **Recommended:** Renal function (BUN, creatinine), ECG (especially with IV administration or suspected hyperkalemia), signs and symptoms of hypokalemia and hyperkalemia. Monitor for GI symptoms with oral therapy.
## Clinical Pearls
* Oral potassium chloride should always be taken with food or a full glass of water to minimize GI irritation and reduce the risk of esophageal ulceration.
* Dilute IV potassium chloride appropriately before administration; never administer as a bolus unless in a dire, monitored emergency.
* Rapid IV infusion of potassium chloride can cause phlebitis, pain, and potentially fatal hyperkalemia and cardiac arrhythmias.
* Consider the source of potassium loss (e.g., diuretic use, vomiting, diarrhea, inadequate intake) when determining therapy.
* Always verify serum potassium levels before and during IV potassium repletion.
***
*Disclaimer: This information is intended for healthcare professionals. Always consult the most current prescribing information and local protocols for definitive patient management.*
